Certara, Inc. (NASDAQ:CERT) Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. trimmed its holdings in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 2.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,921,463 shares of the company's stock after selling 269,667 shares during the quarter. Baillie Gifford & Co. owned approximately 5.58% of Certara worth $156,929,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Advisors Preferred LLC bought a new stake in shares of Certara during the 4th quarter valued at $2,419,000. Trust Point Inc. purchased a new stake in Certara in the fourth quarter worth about $320,000. Pacer Advisors Inc. lifted its position in shares of Certara by 1,704.0% during the 4th quarter. Pacer Advisors Inc. now owns 12,754 shares of the company's stock valued at $224,000 after buying an additional 12,047 shares in the last quarter. Citigroup Inc. grew its stake in shares of Certara by 6.4% during the 3rd quarter. Citigroup Inc. now owns 77,933 shares of the company's stock valued at $1,133,000 after acquiring an additional 4,713 shares during the period. Finally, Comerica Bank purchased a new stake in Certara in the 3rd quarter worth approximately $793,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on CERT. JMP Securities initiated coverage on shares of Certara in a research report on Thursday, April 4th. They set a "market perform" rating on the stock. UBS Group upped their price objective on Certara from $17.00 to $20.00 and gave the stock a "neutral" rating in a research note on Friday, March 1st. Barclays lifted their target price on Certara from $16.00 to $18.00 and gave the company an "equal weight" rating in a research note on Thursday, January 25th. SVB Leerink assumed coverage on Certara in a research note on Monday, February 26th. They issued a "market perform" rating and a $19.00 price target for the company. Finally, Jefferies Financial Group lifted their price objective on shares of Certara from $14.00 to $15.50 and gave the company a "hold" rating in a research report on Friday, March 1st. Seven research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $20.06.

Certara Price Performance

CERT stock traded down $0.05 during trading on Wednesday, hitting $18.46. 565,649 shares of the company's stock traded hands, compared to its average volume of 548,578. The business has a fifty day simple moving average of $17.72 and a 200 day simple moving average of $16.02. Certara, Inc. has a 52 week low of $11.81 and a 52 week high of $24.96. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.62 and a current ratio of 2.62. The stock has a market capitalization of $2.95 billion, a price-to-earnings ratio of -53.43, a P/E/G ratio of 1.95 and a beta of 1.63.

Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings results on Thursday, February 29th. The company reported $0.05 EPS for the quarter, missing analysts' consensus estimates of $0.09 by ($0.04). Certara had a negative net margin of 15.62% and a positive return on equity of 4.33%. The business had revenue of $88.01 million during the quarter, compared to the consensus estimate of $86.80 million. As a group, research analysts expect that Certara, Inc. will post 0.29 EPS for the current fiscal year.

Insider Transactions at Certara

In related news, insider Patrick F. Smith sold 14,427 shares of the firm's stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $16.85, for a total value of $243,094.95. Following the completion of the sale, the insider now directly owns 50,091 shares in the company, valued at $844,033.35. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, insider Patrick F. Smith sold 14,427 shares of the company's stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $16.85, for a total transaction of $243,094.95. Following the transaction, the insider now directly owns 50,091 shares in the company, valued at approximately $844,033.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Richard M. Traynor sold 3,000 shares of the firm's stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $18.00, for a total transaction of $54,000.00. Following the completion of the sale, the senior vice president now directly owns 173,524 shares of the company's stock, valued at approximately $3,123,432. The disclosure for this sale can be found here. In the last 90 days, insiders sold 23,427 shares of company stock worth $405,095. 2.60% of the stock is currently owned by company insiders.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.